Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX-102 in Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
NCT00814372Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of arhalofenate in type 2 diabetes mellitus (T2DM), sponsored by Gilead Sciences. Started Dec 2008; status: terminated.
02
Drugs
arhalofenate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00814372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814372.